Case Reports in Nephrology

Case Reports in Nephrology / 2017 / Article

Case Report | Open Access

Volume 2017 |Article ID 1867349 | 9 pages | https://doi.org/10.1155/2017/1867349

Delayed Manifestation of Shunt Nephritis: A Case Report and Review of the Literature

Academic Editor: Kouichi Hirayama
Received03 Feb 2017
Accepted30 Mar 2017
Published09 Apr 2017

Abstract

We present an unusual case of shunt nephritis in a 39-year-old male who presented 21 years after placement of a ventriculoperitoneal (VP) shunt. He complained of fevers, headaches, dizziness, and urticarial plaques on arms, trunks, and legs and was found to have anemia, low complement levels, elevated serum creatinine, proteinuria, and new onset microhematuria. Blood and urine cultures were negative. Renal biopsy showed features of acute tubulointerstitial nephritis attributed to vancomycin use. Glomeruli showed increased mesangial hypercellularity and segmental endocapillary proliferation. Immunofluorescence showed focal IgM and C3 staining. Electron microscopy revealed small subendothelial electron-dense deposits. Symptoms and renal insufficiency appeared to improve with antibiotic therapy. He was discharged and readmitted 2 months later with similar presentation. CSF grew Propionibacterium acnes and shunt hardware grew coagulase-negative Staphylococcus. He completed an intravenous antibiotic course and was discharged. On 1-month follow-up, skin lesions persisted but he was otherwise asymptomatic. Follow-up labs showed significant improvement. We did a brief systematic review of the literature on shunt nephritis and report our findings on 79 individual cases. In this review, we comment on the presentation, lab findings, pathological features, and management of this rare, potentially fatal, but curable disease entity.

1. Introduction

Hydrocephalus is a pathophysiologic condition due to the accumulation of cerebrospinal fluid (CSF) in the cerebral ventricles [1]. The usual surgical treatment of hydrocephalus is drainage of excess CSF from the brain to another body cavity [shunting]. Historically, the shunts employed were ventriculoatrial (VA), ventriculoperitoneal (VP), and ventriculojugular (VJ) [2, 3], although nonshunt surgical techniques such as endoscopic third ventriculostomy (ETV) are increasingly being accepted [4]. These shunts are associated with a myriad of complications [5, 6] and unique among these is an immunologic phenomenon termed shunt nephritis. This refers to a glomerulonephritis characterized by proteinuria and hematuria which is associated with chronically infected shunts and usually resolves after treatment of the infection, removal of the shunt, or both. Since the description of the first case by Black et al. in 1965 [7], several patients in the literature have been reported to have shunt nephritis. While the overall incidence of shunt infections can range from 7% to 27% [6, 8], the rate of shunt nephritis is considerably much lower with some estimates suggesting its occurrence as low as 0.8% [6].

2. Case Report

A 39-year-old male was admitted for work-up of occult infection due to recurrent fevers, nausea, nonbilious emesis, and occipital headache for three weeks. Prior history was notable for traumatic brain injury in 1995 complicated by subarachnoid hemorrhage with subsequent placement of a ventriculoperitoneal (VP) shunt.

At presentation, the patient was tachycardic (HR: 130 per minute) and febrile (103 F) with urticarial plaques involving trunk, arms, and legs. Initial laboratory studies were notable for serum creatinine of 2.0 mg/dL, hemoglobin of 9.7 g/dL, C3 of 45 mg/dL (normal: 98–162), C4 of 9 mg/dL (normal: 16–43), and rheumatoid factor > 100 international units/mL (normal: <15). Urine microscopy did not reveal dysmorphic red cells or cellular casts. Cerebrospinal fluid showed elevated protein, decreased glucose, and gram stain with moderate leukocytosis but no organisms. Brain computed tomography indicated stable findings of his prior surgeries. The patient was given intravenous vancomycin. During the admission, a 24-hour urine collection revealed 1.4 grams of protein. Blood and cerebrospinal cultures remained negative for growth. However, serum creatinine only improved to 1.6 mg/dL (baseline: 0.98–1.1 mg/dL), so a renal biopsy was performed. Following the biopsy, the patient’s renal insufficiency began improving, and this recovery was thought to be secondary to successful treatment of the infection. Vancomycin was discontinued at this time in light of negative blood cultures and the consultant neurosurgeon did not feel shunt removal was necessary at that time.

With regard to the renal biopsy, the glomeruli showed mesangial hypercellularity and segmental endocapillary proliferation with a single glomerular crescent containing hyaline droplets. Another glomerulus showed a sclerotic segment. There was no evidence of tubular cell vacuoles. The glomerular basement membranes were not thickened. Immunofluorescence was done with fluorochrome conjugated antibodies against human IgG, IgA, IgM, C3, C1q, fibrin, kappa light chain, and lambda light chain, using appropriate controls. A total of four glomeruli were identified. The glomeruli showed focal segmental 2+ IgM and 3+ C3 mesangial staining in three of the glomeruli. The glomeruli were negative for the other stains. The tubular basement membranes were negative for all of the aforementioned stains.

Electron microscopy showed that the foot processes of the podocytes were subtotally effaced. Rare, small, subendothelial osmiophilic electron-dense deposits were identified. Subepithelial deposits were not present. Spikes or duplicated basement membranes were not identified. Segmentally, there were increased numbers of endothelial and mononuclear cells. The mesangial matrix was mildly expanded and there was slightly increased mesangial cellularity with a few osmiophilic electron-dense deposits identified in the mesangium. These electron-dense deposits were not identified in the tubular basement membranes (see Figures 13). The final biopsy report’s diagnosis was acute interstitial nephritis with tubular epithelial necrosis and segmental endocapillary proliferation with increased mesangial hypercellularity.

Two months after the renal biopsy, the patient was readmitted for recurrent symptoms similar to his initial presentation. Vital signs and exam were unremarkable. Laboratory data on readmission were notable for serum creatinine of 1.7 mg/dL, hemoglobin of 8.8 g/dL, C3 of 63 mg/dL, C4 of 15 mg/dL, and rheumatoid factor > 100 international units/mL. Cranial imaging did not show acute findings. On subsequent hospital day, the patient had repeat cerebrospinal fluid studies which showed the presence of Gram-positive organisms. He was restarted on antibiotics and the VP shunt was removed emergently. Cerebrospinal fluid culture resulted in the growth of Propionibacterium acnes and shunt hardware culture grew coagulase-negative Staphylococcus. As per infectious disease consultant’s recommendations, the patient was treated with two weeks of intravenous vancomycin and ampicillin. Repeat blood cultures were negative and no further antimicrobial treatment was required.

At 1-month follow-up in the clinic, the patient had persistent skin lesions; he was otherwise asymptomatic with no headaches, dizziness, nausea, vomiting, fevers, or chills. Microscopic hematuria had completely resolved, C3 had increased to near normal levels, and serum creatinine had improved but not to baseline. Mild proteinuria persisted. Rheumatoid factor was normal. Serum creatinine was 1.2 and hemoglobin was 11.2 g/dL.

3. Discussion

3.1. Methodology

We ran the MeSH terms “shunt” and “nephritis” through 3 medical databases, PUBMED, SCOPUS, and Web of Science, yielding a combined total of 243 search results. After eliminating duplicates, articles not relevant to our search, and those written in a language other than English, we were left with 76 relevant articles that included editorials, case reports, case series, and discussions. We identified 79 individual cases of shunt nephritis from 58 articles in this literature, which we further reviewed [7, 965].

3.2. Pathogenesis

The pathogenetic mechanism of shunt nephritis is not clear. It is hypothesized that the hydrophobic shunt material, acting as a nidus of infection, coupled with biofilm produced by bacteria promotes bacterial growth and bacteremia [10]. The released bacterial antigen results in formation of circulating immune complexes [66, 67], which are deposited in the glomeruli and activate the complement system [29, 32]. In this regard, Dobrin et al. demonstrated low total hemolytic complement, C1–C7, and elevated C9 in 3 patients with shunt nephritis, suggesting classical pathway activation [68]. While Strife et al. noted similar findings in a series of 4 patients with shunt nephritis, they also observed an association of elevated mixed serum cryoglobulins with the hypocomplementemia [69]. These mixed cryoglobulins decreased with treatment of the nephritis along with resolution of hypocomplementemia, suggesting a role in the pathogenesis of the disease. Although the composition of the serum cryoglobulins was different from that of the glomerular deposits, they posited that deposition of these immune complexes in the glomeruli and inability to penetrate the basement membrane result in subendothelial immune complex accumulation, mesangial proliferation, and mesangial interposition, all frequently encountered on renal pathology [70]. Several authors have also demonstrated bacterial antigens in the glomeruli, further bolstering this hypothesis [13, 14, 25, 45]. On the contrary, Vella et al. propose that the source of antigen is the bioprosthetic shunt material which independently triggers a humoral immune response that results in shunt nephritis [71].

3.3. Microbiology

Analysis of microbiology from the 79 patients we reviewed is shown in Table 1. Approximately half of the CSF and shunt cultures were negative, while close to one-third of the blood cultures were negative. Four patients had negative blood, CSF, and shunt cultures, so-called culture-negative shunt nephritis [9, 43, 60, 61]. When cultures were positive, the coagulase-negative Staphylococcal (CNS) species (including Staphylococcus epidermidis and Staphylococcus albus) were predominant, irrespective of the type of culture specimen. These were closely followed by Propionibacterium acnes (P. acnes). One patient had a CSF culture positive for more than one bacterium [72], while another grew different bacteria in blood and CSF [9]. Our patient grew P. acnes in CSF and shunt cultures grew Staphylococcus epidermidis (mixed infection) which is unusual. It is important to note that, in the past, P. acnes and CNS were considered contaminants. But the demonstration of the respective bacterial antigens in the blood and glomeruli of patients with shunt nephritis suggests a pathogenic role in the disease process [11, 32]. Of note also is the fact that it may take up to 14 days to grow Propionibacterium in cultures [73] and the diagnosis may be missed by terminating cultures prematurely.


MicroorganismBlood cultures
(%)
CSF cultures
(%)
Shunt cultures
(%)

275653
C. bovis310
M. bovis110
Diphtheroids331
Micrococcus314
G. morbillorum111
P. aeruginosa104
S. viridans100
P. acnes10610
Staphylococcus epidermidis19119
Staphylococcus albus15911
Coagulase-negative Staphylococcus 1385
Proteus100
Staphylococcus aureus311
Mixed infection010

Total100100100

results reported as negative or not reported at all.
3.4. Epidemiology

From the 79 patients with shunt nephritis that we reviewed, there is a slight male predominance, that is, 43 males versus 36 females. Patients’ ages at presentation range from 1 year to 74 years, with an average age of 21 years. More than 75% of patients had a VA shunt, with a minority having either a VP or VJ shunt. 10% of patients had their shunt modality revised before onset of nephritis. Shunt characteristics are outlined in Table 2. We defined shunt duration as time from index insertion of shunt to onset of first nephritic symptoms irrespective of shunt revision surgery. We recognize that revision surgeries may influence shunt infections, but this information was not easily obtainable from the literature we reviewed. Our shunt duration definition is a departure from the definition used in a recent review, that is, time from last shunt surgery to onset of clinical signs and symptoms [74]. In our series, average shunt duration was 5.8 years. The range of shunt duration was 1 month to 20 years. Our patient presented 21 years after VP shunt placement, making his case rather unusual.


Type of Shunt%

Ventriculoatrial (VA)76
Ventriculojugular (VJ)9
Ventriculoperitoneal (VP)5
Revisions, VP/VA10

Total100

3.5. Clinical Presentation

Shunt nephritis may present with variable nonspecific signs and symptoms, most commonly hematuria, fever, hypertension, and hepatosplenomegaly (see Table 3). Less commonly, shunt nephritis may manifest with skin rashes and arthralgia. One case report noted very unusual and unexplained symptoms of fevers and myalgia only when the patient was taking showers [16]. Anemia is thought to be due to decreased erythropoietin production and/or iron deficiency [50] and hepatosplenomegaly secondary to removal of formed immune complexes by the reticuloendothelial system [75]. Arthritis and arthralgia have been attributed to the formation of circulating immune complexes in the synovium [56]. The pathophysiology of urticaria and skin rashes is less well understood but is thought to be immune-mediated [34]. Common lab abnormalities include proteinuria, anemia, hypocomplementemia, and elevated serum creatinine. Positive serum cryoglobulins and rheumatoid factor are seen infrequently.


Clinical finding%

Hematuria87
Fever67
Hypertension35
Hepatosplenomegaly23
Edema15
Skin rash8
Splenomegaly6
Arthralgia4
Altered mental status4
Seizure4
Failure to thrive4

Nephrotic range proteinuria can be as massive as 38 g per day [63] and the anemia can be severe with hemoglobin as low as 4 g/dL [55]. Acute renal failure (ARF), defined as significant rise in serum creatinine above baseline or significant decline in estimated glomerular filtration rate (GFR), was reported in 46 patients. However, unlike serum creatinine, ARF was not consistently or uniformly reported in all the literatures reviewed. We therefore opted to use serum creatinine of greater than or equal to 1 (arbitrary value) as an alternative marker of renal dysfunction, even though it is inherently less accurate than the ARF definition cited above. Using this measure, over half of the patients reviewed had abnormal renal function (see Table 4). We do recognize the limitations of using serum creatinine as a gauge of renal function since it does not account for ARF in patients with baseline chronic kidney disease. But since no other measure of renal function was consistently reported in all of the reviewed cases, we settled for serum creatinine as a compromise. Some patients do present with positive anti-neutrophil cytoplasmic antibody (ANCA) titers, all antiproteinase 3 positive, with decrease in titers after treatment of the shunt nephritis [15, 31, 36, 42]. The exact mechanism of ANCA production is unclear [31]. The low complements, as discussed previously, may represent activation of the classical pathway as the disease unfolds [69]. For disease screening and diagnostic purposes, Bayston et al. have proposed the use of Anti Staphylococcus Epidermidis Titer (ASET) after they demonstrated that ASET rises predictably in patients with VA shunts colonized by Staphylococcus epidermidis [61, 76, 77]. While the ASET is a welcome addition to the diagnostic armamentarium, no single symptom, sign, or lab finding should be considered in isolation when shunt nephritis is suspected. Wyatt et al. suggest that complement levels be monitored until normalization and only be repeated when a relapse of nephritis is suspected [62]. Our patient presented with fever, anemia, microscopic hematuria, proteinuria, hypocomplementemia, renal insufficiency, positive rheumatoid factor, and urticarial plaques, all consistent with features of shunt nephritis described above.


Lab findingNumber

ProteinuriaMedian, 19.4 g (range: 0.5–38)68
AnemiaAvg., 7.8 g/dL (range: 4–11.5)58
Serum complementsLow57
Serum creatinineGreater than 1/abnormal43
Acute renal failureSignificant rise in serum creatinine above baseline or decline in estimated GFR46
Serum cryoglobulinsPositive7
Serum ANCAPositive4
Serum RFPositive4

3.6. Pathology

Of the 79 shunt nephritis patients reviewed, 62 had renal biopsies with 8 of these patients having repeat biopsies after treatment of the nephritis. The majority of these biopsies reveal a mesangial proliferative and membranoproliferative (MPGN) pattern of glomerulonephritis on light microscopy (see Table 5).


Biopsy findings%

Mesangial proliferative GN52
MPGN45
Amyloidosis2
End-stage kidney2

Total100

Immunofluorescence was done in approximately two-thirds of the renal biopsies with mesangial IgM, C1q, and C3 deposition being the most common finding. Relative intensities of immunoglobulin deposition were inconsistently reported, so we excluded them from our analysis (see Table 6). Out of the 62 biopsies reported in this literature review, electron microscopy was performed in only 28 instances, of which 18 (64%) had subendothelial deposits and 11 (39%) had mesangial deposits. Only 1 biopsy reported subepithelial deposits [53]. This further confirms the immune complex nature of the disease. Six biopsies had crescents [9, 19, 21, 53, 59, 64]. All the patients that had repeat biopsies after treatment of shunt nephritis demonstrated improvement in histologic findings [24, 28, 59, 60, 62, 63, 65]. One renal biopsy was initially read as amyloidosis but later retrospectively changed to “shunt nephritis” after signs and symptoms resolved with therapy [78].


Immunofluorescence% (out of 42)

IgM83
C371
IgG57
C1q83
IGA26
C424
Lambda5
Positive complement5

Our patient’s biopsy report showed features of tubulointerstitial nephritis that was attributed to vancomycin use. The glomeruli showed increased mesangial hypercellularity and segmental endocapillary proliferation, while immunofluorescence was positive for IgM and C3. Electron microscopy showed subendothelial deposits (see Figure 3).

3.7. Treatment

Therapy for this unique form of glomerulonephritis is multifaceted, including medical (antibiotics) and surgical approaches (shunt removal). Even though some cases of shunt nephritis show improvement with antibiotics alone [13, 14, 37, 40, 44, 54], best results are achieved with removal of the infected shunt, along with a course of IV antibiotics to clear the infection. If hydrocephalus remains a clinical concern, a temporary external ventricular drain may be placed. Some authors advocate administration of intraventricular antibiotics during this period [74]. Once the infection is resolved, it may be prudent to consider nonshunt surgical techniques such as ventriculocisternostomy for persistent hydrocephalus [16]. If a shunt is still necessary, VP shunts appear to be more preferable to VA or VJ shunts (see Table 7). The use of antibiotic-coated shunts and perioperative antibiotic prophylaxis may play a role in the prevention of shunt infection [79, 80].


Full renal recoveryPartial renal recoveryProgressed to ESRDDeath

Shunt removed161932
Shunt replaced5611
Converted to VP shunt7900
Antibiotics alone0603

294046

Full renal recovery: complete resolution of hematuria, proteinuria, and renal dysfunction. Partial renal recovery: resolution of 1 or more of hematuria, proteinuria, and renal dysfunction but not all.
of deceased kidney donor with shunt nephritis is excluded.

For the purposes of this review, we defined full renal recovery as complete resolution of hematuria, proteinuria, and renal dysfunction, while partial renal recovery was defined as resolution of one or more of hematuria, proteinuria, or renal dysfunction but not all. As described earlier, renal dysfunction was arbitrarily defined as serum creatinine greater than or equal to 1. The average time to achieve renal recovery (complete or partial resolution of hematuria, proteinuria, and renal dysfunction) is 9.5 months. As illustrated in Table 8, the majority of patients with renal recovery had the shunt removed. From our analysis, it appears that patients with full renal recovery had shorter average duration of shunt placement as compared to the ones with partial renal recovery and those that progressed to ESRD. This may suggest that longer residence of an infected shunt correlates with worse renal outcomes. While concurrent antibiotic therapy may play an additional role in renal recovery, only a small minority of patients in this review did not receive any antibiotics (see Table 9). Our brief analysis did not account for other factors, such as age or significant comorbidities, which may influence renal recovery in shunt nephritis.


%Time to renal recovery in months (range)Average shunt duration in years
(range)

Death84.79 (3.5–15)
Progressed to ESRD58.75 (4–14)
Full renal recovery3710.8 (1–48)4.94 (0.25–19)
Partial renal recovery518.4 (0.25–72)6.28. (0.1–20)

Total1009.5 (0.25–72)5.8 (0.120)

Full renal recovery: complete resolution of hematuria, proteinuria, and renal dysfunction. Partial renal recovery: resolution of 1 or more of hematuria, proteinuria, and renal dysfunction but not all.

Full renal recoveryPartial renal recoveryProgressed to ESRDDeath

Shunt removed81%84%100%100%
Shunt replaced80%100%100%100%
Converted to VP shunt71%100%

Of the 6 deaths that were reported, only 1 was conclusively attributed to renal failure [40], with the rest being unknown or secondary to surgical complications of hydrocephalus [7, 32, 49, 64]. It appears that immune suppression therapy does not attenuate this disease process and may even contribute to negative outcomes [31, 32, 34, 64]. Indeed, one patient got steroids for 2 years followed by cyclophosphamide for presumed ANCA disease, but nephritis resolved only after removal of the shunt [15]. An unusual case of kidney donation by a deceased patient with shunt nephritis described remarkable resolution of renal disease in the recipient [26]; this observation further supports the notion that removal of the injurious immunologic environment is a means of cure. Our patient had the shunt in place for 21 years; the infection was initially treated with antibiotics, but meaningful symptomatic and renal recovery was not achieved until the shunt was removed. In hindsight, our patient’s initial presumed diagnosis of acute interstitial nephritis attributed to vancomycin therapy was flawed and should have been revised to “shunt nephritis.”

4. Conclusion

Shunt nephritis may manifest with many nonspecific symptoms, signs, and lab findings. If not quickly recognized, diagnostic delay may lead to irreversible chronic renal disease and possibly death. So nephrologists should maintain a high degree of suspicion in patients who present with indwelling CSF shunts and renal disease suggestive of nephritis.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

Dr. Balakuntalam Kasinath and Dr. Brent Wagner helped with the editing of this manuscript.

References

  1. K. T. Kahle, A. V. Kulkarni, D. D. Limbrick Jr., and B. C. Warf, “Hydrocephalus in children,” The Lancet, vol. 387, no. 10020, pp. 788–799, 2016. View at: Publisher Site | Google Scholar
  2. A. Aschoff, P. Kremer, B. Hashemi, and S. Kunze, “The scientific history of hydrocephalus and its treatment,” Neurosurgical Review, vol. 22, no. 2-3, pp. 67–93, 1999. View at: Publisher Site | Google Scholar
  3. R. S. Tubbs, P. Vahedi, M. Loukas, and A. A. Cohen-Gadol, “Harvey Cushing's experience with treating childhood hydrocephalus: in his own words,” Child's Nervous System, vol. 27, no. 6, pp. 995–999, 2011. View at: Publisher Site | Google Scholar
  4. M. G. Hamilton, “Treatment of hydrocephalus in adults,” Seminars in Pediatric Neurology, vol. 16, no. 1, pp. 34–41, 2009. View at: Publisher Site | Google Scholar
  5. S. Iglesias, B. Ros, Á. Martín et al., “Surgical outcome of the shunt: 15-year experience in a single institution,” Child's Nervous System, vol. 32, no. 12, pp. 2377–2385, 2016. View at: Publisher Site | Google Scholar
  6. A. R. Al-Schameri, J. Hamed, G. Baltsavias et al., “Ventriculoatrial shunts in adults, incidence of infection, and significant risk factors: a single-center experience,” World Neurosurgery, vol. 94, pp. 345–351, 2016. View at: Publisher Site | Google Scholar
  7. J. A. Black, D. N. Challacombe, and B. G. Ockenden, “Nephrotic syndrome associated with bacteræmia after shunt operations for hydrocephalus,” The Lancet, vol. 286, no. 7419, pp. 921–924, 1965. View at: Publisher Site | Google Scholar
  8. S. C. Schoenbaum, P. Gardner, and J. Shillito, “Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy,” Journal of Infectious Diseases, vol. 131, no. 5, pp. 543–552, 1975. View at: Publisher Site | Google Scholar
  9. R. S. Arze, H. Rashid, R. Morley, M. K. Ward, and D. N. Kerr, “Shunt nephritis: report of two cases and review of the literature,” Clinical Nephrology, vol. 19, no. 1, pp. 48–53, 1983. View at: Google Scholar
  10. R. A. Balogun, J. Palmisano, A. A. Kaplan, H. Khurshid, H. Yamase, and N. D. Adams, “Shunt nephritis from Propionibacterium acnes in a solitary kidney,” American Journal of Kidney Diseases, vol. 38, no. 4, article E18, 2001. View at: Google Scholar
  11. B. A. Beeler, J. G. Crowder, J. W. Smith, and A. White, “Propionibacterium acnes: pathogen in central nervous system shunt infection. Report of three cases including immune complex glomerulonephritis,” The American Journal of Medicine, vol. 61, no. 6, pp. 935–938, 1976. View at: Publisher Site | Google Scholar
  12. R. Bogdanović, B. Marjanović, V. Nikolić et al., “Shunt nephritis associated with Moraxella bovis,” Acta Paediatrica, vol. 85, no. 7, pp. 882–883, 1996. View at: Publisher Site | Google Scholar
  13. W. K. Bolton, M. A. Sande, and D. E. Normansell, “Shunt nephritis with Corynebacterium bovis (C.b.): successful therapy (Rx) with antibiotics,” Kidney International, vol. 6, no. 6, article 26, 1974. View at: Google Scholar
  14. W. K. Bolton, M. A. Sande, D. E. Normansell, B. C. Sturgill, and F. B. Westervelt Jr., “Ventriculojugular shunt nephritis with Corynebacterium bovis. Successful therapy with antibiotics,” The American Journal of Medicine, vol. 59, no. 3, pp. 417–423, 1975. View at: Publisher Site | Google Scholar
  15. H. Bonarek, F. Bonnet, C. Delclaux, C. Deminière, V. De Précigout, and M. Aparicio, “Reversal of c-ANCA positive mesangiocapillary glomerulonephritis after removal of an infected cysto-atrial shunt,” Nephrology Dialysis Transplantation, vol. 14, no. 7, pp. 1771–1773, 1999. View at: Publisher Site | Google Scholar
  16. G. Burström, M. Andresen, J. Bartek, and A. Fytagoridis, “Subacute bacterial endocarditis and subsequent shunt nephritis from ventriculoatrial shunting 14years after shunt implantation,” BMJ Case Reports, vol. 2014, 2014. View at: Publisher Site | Google Scholar
  17. P. Byrne, P. McArdle, G. K. Hayes, M. Archer, A. R. Pate, and S. Dundon, “Shunt nephritis,” Irish Medical Journal, vol. 75, no. 9, p. 326, 1982. View at: Google Scholar
  18. A. Cornér, K. Kaartinen, S. Aaltonen, A. Räisänen-Sokolowski, H. Helin, and E. Honkanen, “Membranoproliferative glomerulonephritis complicating Propionibacterium acnes infection,” Clinical Kidney Journal, vol. 6, no. 1, pp. 35–39, 2013. View at: Publisher Site | Google Scholar
  19. R. S. Dobrin, N. K. Day, P. G. Quie et al., “The role of complement, immunoglobulin and bacterial antigen in coagulase-negative staphylococcal shunt nephritis,” The American Journal of Medicine, vol. 59, no. 5, pp. 660–673, 1975. View at: Publisher Site | Google Scholar
  20. H. J. Dodd, H. J. Goldsmith, and J. L. Verbov, “Necrotizing cutaneous vasculitis occurring as an early feature of “shunt nephritis”,” Clinical and Experimental Dermatology, vol. 10, no. 3, pp. 284–287, 1985. View at: Publisher Site | Google Scholar
  21. K. P. Dawson, H. Lees, W. M. I. Smeeton, and P. B. Herdson, “Glomerulonephritis associated with an infected ventriculo-atrial shunt,” New Zealand Medical Journal, vol. 91, no. 659, pp. 342–344, 1980. View at: Google Scholar
  22. J. A. Frank Jr., H. S. Friedman, D. M. Davidson, J. M. Falletta, and T. R. Kinney, “Propionibacterium shunt nephritis in two adolescents with medulloblastoma,” Cancer, vol. 52, no. 2, pp. 330–333, 1983. View at: Publisher Site | Google Scholar
  23. H. L. Finney and T. S. Roberts, “Nephritis secondary to chronic cerebrospinal fluid—vascular shunt infection: ‘shunt nephritis’,” Child's Brain, vol. 6, no. 4, pp. 189–193, 1980. View at: Google Scholar
  24. Y. Fukuda, Y. Ohtomo, K. Kaneko, and K. Yabuta, “Pathologic and laboratory dynamics following the removal of the shunt in shunt nephritis,” American Journal of Nephrology, vol. 13, no. 1, pp. 78–82, 1993. View at: Publisher Site | Google Scholar
  25. A. B. J. Groeneveld, F. E. Nommensen, H. Mullink, E. C. Ooms, and W. A. Bode, “Shunt nephritis associated with Propionibacterium acnes with demonstration of the antigen in the glomeruli,” Nephron, vol. 32, no. 4, pp. 365–369, 1982. View at: Google Scholar
  26. F. Guerville, S. Lepreux, D. Morel et al., “Transplantation with pathologic kidneys to improve the pool of donors: an example of shunt nephritis,” Transplantation, vol. 93, no. 8, pp. e34–e35, 2012. View at: Publisher Site | Google Scholar
  27. M. Guner, K. Yucesoy, and H. Ozer, “Shunt nephritis,” Turkish Neurosurgery, vol. 8, no. 1-2, pp. 47–49, 1998. View at: Google Scholar
  28. G. M. Halmagyi and J. S. Horvath, “Acute glomerulonephritis in an adult with infected ventriculoatrial shunt,” Medical Journal of Australia, vol. 1, no. 4, pp. 136–137, 1979. View at: Google Scholar
  29. G. D. Harkiss, D. L. Brown, and D. B. Evans, “Longitudinal study of circulating immune complexes in a patient with Staphylococcus albus-induced shunt nephritis,” Clinical and Experimental Immunology, vol. 37, no. 2, pp. 228–238, 1979. View at: Google Scholar
  30. D. Hettiarachchi, R. Gajanayaka, and M. Gilbert, “A case of shunt nephritis induced by propionibacterium acnes,” American Journal of Kidney Diseases, vol. 67, no. 5, p. A53, 2016. View at: Publisher Site | Google Scholar
  31. Y. Iwata, S. Ohta, K. Kawai et al., “Shunt nephritis with positive titers for ANCA specific for proteinase 3,” American Journal of Kidney Diseases, vol. 43, no. 5, pp. e11–e16, 2004. View at: Google Scholar
  32. D. B. Kaufman and R. McIntosh, “The pathogenesis of the renal lesion in a patient with Streptococcal disease, infected ventriculoatrial shunt, cryoglobulinemia and nephritis,” The American Journal of Medicine, vol. 50, no. 2, pp. 262–268, 1971. View at: Publisher Site | Google Scholar
  33. K. Kiryluk, D. Preddie, V. D. D'Agati, and R. Isom, “A young man with Propionibacterium acnes-induced shunt nephritis,” Kidney International, vol. 73, no. 12, pp. 1434–1440, 2008. View at: Publisher Site | Google Scholar
  34. P. Kravitz and N. I. Stahl, “Urticarial vasculitis, immune complex disease, and an infected ventriculoatrial shunt,” Cutis, vol. 36, no. 2, pp. 135–141, 1985. View at: Google Scholar
  35. M. Kubota, Y. Sakata, N. Saeki, A. Yamaura, and M. Ogawa, “A case of shunt nephritis diagnosed 17 years after ventriculoatrial shunt implantation,” Clinical Neurology and Neurosurgery, vol. 103, no. 4, pp. 245–246, 2001. View at: Publisher Site | Google Scholar
  36. B. Kumar and N. Munshi, “Antineutrophil cytoplasmic autoantibody specific for proteinase 3 in a patient with shunt nephritis induced by Staphylococcus epidermidis,” American Journal of Kidney Diseases, vol. 53, no. 4, p. A48, 2009. View at: Google Scholar
  37. H. S. Lee, S. H. Cha, B. S. Cho, and M. H. Yang, “A case of shunt nephritis,” Journal of Korean Medical Science, vol. 10, no. 1, pp. 62–65, 1995. View at: Publisher Site | Google Scholar
  38. N. Legoupil, P. Ronco, and F. Berenbaum, “Arthritis-related shunt nephritis in an adult,” Rheumatology, vol. 42, no. 5, pp. 698–699, 2003. View at: Publisher Site | Google Scholar
  39. G. Marini, P. W. Gabriele, B. Tanghetti, A. Castellani, G. Olivetti, and E. Zunin, “Membranoproliferative glomerulonephritis associated with infected ventriculoatrial shunt. Report of two cases recovered after removal of the shunt,” Modern Problems in Paediatrics, vol. 18, pp. 207–210, 1976. View at: Google Scholar
  40. S. A. McKenzie and K. Hayden, “Two cases of ‘shunt nephritis’,” Pediatrics, vol. 54, no. 6, pp. 806–808, 1974. View at: Google Scholar
  41. S. W. Moss, N. E. Gary, and R. P. Eisinger, “Nephritis associated with a diphtheroid-infected cerebrospinal fluid shunt,” The American Journal of Medicine, vol. 63, no. 2, pp. 318–319, 1977. View at: Publisher Site | Google Scholar
  42. T. Nagashima, D. Hirata, H. Yamamoto, H. Okazaki, and S. Minota, “Antineutrophil cytoplasmic autoantibody specific for proteinase 3 in a patient with shunt nephritis induced by Gemella morbillorum,” American Journal of Kidney Diseases, vol. 37, no. 5, article E38, 2001. View at: Google Scholar
  43. H. N. Noe and S. Roy III, “Shunt nephritis,” The Journal of Urology, vol. 125, no. 5, pp. 731–733, 1981. View at: Google Scholar
  44. E. Noiri, S. Kuwata, K. Nosaka et al., “Shunt nephritis: efficacy of an antibiotic trial for clinical diagnosis,” Internal Medicine, vol. 32, no. 4, pp. 291–294, 1993. View at: Publisher Site | Google Scholar
  45. S. O'Regan and S. P. Makker, “Shunt nephritis: demonstration of diphtheroid antigen in glomeruli,” American Journal of the Medical Sciences, vol. 278, no. 2, pp. 161–172, 1979. View at: Publisher Site | Google Scholar
  46. C. Paliouras, F. Lamprianou, G. Ntetskas et al., “Membranoproliferative glomerulonephritis type 1 secondary to an infected ventriculoperitoneal shunt: a case report,” BANTAO Journal, vol. 12, no. 2, pp. 117–119, 2014. View at: Google Scholar
  47. W. Peeters, M. Mussche, I. Becaus, and S. Ringoir, “Shunt nephritis,” Clinical Nephrology, vol. 9, no. 3, pp. 122–125, 1978. View at: Google Scholar
  48. B. J. Pereira, S. Kumari, K. L. Gupta et al., “Shunt nephritis associated with Staphylococcus aureus septicaemia,” The Journal of the Association of Physicians of India, vol. 35, no. 11, pp. 796–798, 1987. View at: Google Scholar
  49. C. Ravindranath and F. J. Takacs, “Shunt nephritis glomerulonephritis associated with ventriculoatrial shunts,” Lahey Clinic Foundation Bulletin, vol. 23, no. 2, pp. 48–52, 1974. View at: Google Scholar
  50. S. Rifkinson-Mann, N. Rifkinson, and T. Leong, “Shunt nephritis. Case report,” Journal of Neurosurgery, vol. 74, no. 4, pp. 656–659, 1991. View at: Publisher Site | Google Scholar
  51. M. Rodriguez Girones and A. Genoves, “Bacteraemia by P. aeruginosa associated with nephrotic syndrome after shunt operation for hydrocephalus,” Chemotherapy, vol. 23, supplement 1, pp. 423–427, 1977. View at: Publisher Site | Google Scholar
  52. M. Schoeneman, B. Bennett, and I. Greifer, “Shunt nephritis progressing to chronic renal failure,” American Journal of Kidney Diseases, vol. 2, no. 3, pp. 375–377, 1982. View at: Publisher Site | Google Scholar
  53. M. Searle and H. A. Lee, “Ventriculo-atrial shunt nephritis,” Postgraduate Medical Journal, vol. 58, no. 683, pp. 566–569, 1982. View at: Publisher Site | Google Scholar
  54. U. Setz, U. Frank, K. Anding, F. D. Daschner, and A. Garbe, “Shunt nephritis associated with Propionibacterium acnes,” Infection, vol. 22, no. 2, pp. 99–101, 1994. View at: Publisher Site | Google Scholar
  55. U. G. Stauffer, “'Shunt nephritis': diffuse glomerulonephritis complicating ventriculo-atrial shunts,” Developmental Medicine and Child Neurology. Supplement, vol. 22, supplement 22, p. 161, 1970. View at: Google Scholar
  56. E. J. ter Borg, M. H. Van Rijswijk, and C. G. M. Kallenberg, “Transient arthritis with positive tests for rheumatoid factor as presenting sign of shunt nephritis,” Annals of the Rheumatic Diseases, vol. 50, no. 3, pp. 182–183, 1991. View at: Publisher Site | Google Scholar
  57. M. Thomas, M. Ralston, J. Harkness, and J. Hayes, “Resolution of shunt nephritis,” Australian and New Zealand Journal of Medicine, vol. 7, no. 4, p. 452, 1977. View at: Google Scholar
  58. R. Topaloglu, A. Bakkloglu, U. Saatci, N. Basbas, and T. Ozgen, “Consequences of delayed treatment on shunt nephrities. A case report,” Turkish Neurosurgery, vol. 1, no. 4, pp. 174–175, 1990. View at: Google Scholar
  59. Y. Wakabayashi, Y. Kobayashi, and H. Shigematsu, “Shunt nephritis: histological dynamics following removal of the shunt. Case report and review of the literature,” Nephron, vol. 40, no. 1, pp. 111–117, 1985. View at: Google Scholar
  60. W. Wegmann and E. P. Leumann, “Glomerulonephritis associated with (infected) ventriculo-atrial shunt,” Virchows Archiv. A, Pathological Anatomy and Histology, vol. 359, no. 3, pp. 185–200, 1973. View at: Publisher Site | Google Scholar
  61. H. Wood, G. McCarthy, R. Fluck, and R. Bayston, “Shunt nephritis: fortuitous diagnosis and confirmation by serology (ASET),” European Journal of Pediatric Surgery, Supplement, vol. 8, supplement 1, pp. 66–67, 1998. View at: Google Scholar
  62. R. J. Wyatt, J. W. Walsh, and N. H. Holland, “Shunt nephritis. Role of the complement system in its pathogenesis and management,” Journal of Neurosurgery, vol. 55, no. 1, pp. 99–107, 1981. View at: Publisher Site | Google Scholar
  63. B. P. Yeh, H. F. Young, P. F. Schatzki, and E. S. Bear, “Immune complex disease associated with an infected ventriculo-jugular shunt: a curable form of glomerulonephritis,” Southern Medical Journal, vol. 70, no. 9, pp. 1141–1146, 1977. View at: Publisher Site | Google Scholar
  64. I. Zamora, A. Lurbe, and A. Alvarez-Garijo, “Shunt nephritis: a report on five children,” Child's Brain, vol. 11, no. 3, pp. 183–187, 1984. View at: Google Scholar
  65. C. Zunin, A. Castellani, G. Olivetti, G. Marini, and P. W. Gabriele, “Membranoproliferative glomerulonephritis associated with infected ventriculoatrial shunt: report of two cases recovered after removal of the shunt,” Pathologica, vol. 69, no. 991-992, pp. 297–305, 1977. View at: Google Scholar
  66. W. Samtleben, G. Bauriedel, T. Bosch, C. Goetz, B. Klare, and H. J. Gurland, “Renal complications of infected ventriculoatrial shunts,” Artificial Organs, vol. 17, no. 8, pp. 695–701, 1993. View at: Google Scholar
  67. F. P. Schena, G. Pertosa, A. Pastore, A. De Tommasi, M. T. Montagna, and L. Bonomo, “Circulating immune complexes in infected ventriculoatrial and ventriculoperitoneal shunts,” Journal of Clinical Immunology, vol. 3, no. 2, pp. 173–177, 1983. View at: Publisher Site | Google Scholar
  68. R. Dobrin, N. Day, P. Quie et al., “The role of complement, immunoglobulin and bacterial antigen in coagulase-negative staphylococcal shunt nephritis,” The American Journal of Medicine, vol. 59, no. 5, pp. 660–673, 1975. View at: Publisher Site | Google Scholar
  69. C. F. Strife, B. M. McDonald, E. J. Ruley, A. J. McAdams, and C. D. West, “Shunt nephritis: the nature of the serum cryoglobulins and their relation to the complement profile,” Journal of Pediatrics, vol. 88, no. 3, pp. 403–413, 1976. View at: Publisher Site | Google Scholar
  70. C. Strife, B. McDonald, E. Ruley, A. McAdams, and C. West, “Shunt nephritis: the nature of the serum cryoglobulins and their relation to the complement profile,” The Journal of Pediatrics, vol. 88, no. 3, pp. 403–413, 1976. View at: Publisher Site | Google Scholar
  71. J. Vella, M. Carmody, E. Campbell, O. Browne, G. Doyle, and J. Donohoe, “Glomerulonephritis after ventriculo-atrial shunt,” QJM, vol. 88, no. 12, pp. 911–918, 1995. View at: Publisher Site | Google Scholar
  72. P. Futrakul, L. O. Surapathana, and R. A. Campbell, “Review of shunt nephritis,” Journal of the Medical Association of Thailand, vol. 53, no. 4, pp. 265–274, 1970. View at: Google Scholar
  73. E. D. Everett, T. C. Eickhoff, and R. H. Simon, “Cerebrospinal fluid shunt infections with anaerobic diphtheroids (Propionibacterium species),” Journal of Neurosurgery, vol. 44, no. 5, pp. 580–584, 1976. View at: Publisher Site | Google Scholar
  74. D. Haffner, F. Schindera, A. Aschoff, S. Matthias, R. Waldherr, and K. Schärer, “The clinical spectrum of shunt nephritis,” Nephrology Dialysis Transplantation, vol. 12, no. 6, pp. 1143–1148, 1997. View at: Publisher Site | Google Scholar
  75. S. L. Wald and R. L. McLaurin, “Shunt-associated glomerulonephritis,” Neurosurgery, vol. 3, no. 2, pp. 146–150, 1978. View at: Publisher Site | Google Scholar
  76. R. Bayston and J. Rodgers, “Role of serological tests in the diagnosis of immune complex disease in infection of ventriculoatrial shunts for hydrocephalus,” European Journal of Clinical Microbiology & Infectious Diseases, vol. 13, no. 5, pp. 417–420, 1994. View at: Publisher Site | Google Scholar
  77. R. Bayston, J. Rodgers, and Z. B. Tabara, “Ventriculoatrial shunt colonisation and immune complex nephritis,” European Journal of Pediatric Surgery, vol. 1, supplement 1, pp. 46–47, 1991. View at: Google Scholar
  78. H. Lee Finney and T. S. Roberts, “Nephritis secondary to chronic cerebrospinal fluid—vascular shunt infection: “Shunt nephritis”,” Pediatric Neurosurgery, vol. 6, no. 4, pp. 189–193, 1980. View at: Publisher Site | Google Scholar
  79. A. A. Konstantelias, K. Z. Vardakas, K. A. Polyzos, G. S. Tansarli, and M. E. Falagas, “Antimicrobial-impregnated and -coated shunt catheters for prevention of infections in patients with hydrocephalus: a systematic review and meta-analysis,” Journal of Neurosurgery, vol. 122, no. 5, pp. 1096–1112, 2015. View at: Publisher Site | Google Scholar
  80. X. Wu, Q. Liu, X. Jiang, and T. Zhang, “Prevention options for ventriculoperitoneal shunt infections: a retrospective analysis during a five-year period,” International Journal of Clinical and Experimental Medicine, vol. 8, no. 10, pp. 19775–19780, 2015. View at: Google Scholar

Copyright © 2017 Michael Babigumira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

2599 Views | 507 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.